Used in pharmaceutical synthesis as an intermediate in the development of targeted protein degradation therapies, particularly in the design of PROTACs (proteolysis-targeting chimeras). Its structure enables linkage between E3 ubiquitin ligase ligands and target protein binders, facilitating selective degradation of disease-related proteins. Commonly employed in research for oncology and neurodegenerative disease drug discovery due to its stability and modifiable functional groups. Also utilized in solid-phase synthesis and medicinal chemistry optimization for improved pharmacokinetic properties.